- Home
- CULP vs SNTI Comparison
CULP vs SNTI Comparison
Compare CULP & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CULP
- SNTI
- Stock Information
- Founded
- CULP 1972
- SNTI 2016
- Country
- CULP United States
- SNTI United States
- Employees
- CULP N/A
- SNTI N/A
- Industry
- CULP Textiles
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- CULP Consumer Discretionary
- SNTI Health Care
- Exchange
- CULP Nasdaq
- SNTI Nasdaq
- Market Cap
- CULP 52.7M
- SNTI 53.6M
- IPO Year
- CULP N/A
- SNTI N/A
- Fundamental
- Price
- CULP $3.79
- SNTI $1.94
- Analyst Decision
- CULP
- SNTI Strong Buy
- Analyst Count
- CULP 0
- SNTI 3
- Target Price
- CULP N/A
- SNTI $9.67
- AVG Volume (30 Days)
- CULP 17.2K
- SNTI 277.2K
- Earning Date
- CULP 12-03-2025
- SNTI 11-12-2025
- Dividend Yield
- CULP N/A
- SNTI N/A
- EPS Growth
- CULP N/A
- SNTI N/A
- EPS
- CULP N/A
- SNTI N/A
- Revenue
- CULP $207,391,000.00
- SNTI N/A
- Revenue This Year
- CULP $1.93
- SNTI N/A
- Revenue Next Year
- CULP $2.77
- SNTI $150.00
- P/E Ratio
- CULP N/A
- SNTI N/A
- Revenue Growth
- CULP N/A
- SNTI N/A
- 52 Week Low
- CULP $3.42
- SNTI $1.26
- 52 Week High
- CULP $5.94
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- CULP 27.16
- SNTI 50.21
- Support Level
- CULP $3.95
- SNTI $1.80
- Resistance Level
- CULP $4.05
- SNTI $2.04
- Average True Range (ATR)
- CULP 0.12
- SNTI 0.16
- MACD
- CULP -0.04
- SNTI -0.05
- Stochastic Oscillator
- CULP 4.49
- SNTI 24.49
About CULP Culp Inc.
Culp Inc manufactures, markets mattress fabrics for bedding and upholstery fabrics for residential, commercial, and hospitality furnishings. The company has two operating segments: Mattress fabrics, which generate maximum revenue, and Upholstery fabrics. The mattress fabrics segment manufactures, sources, and sells fabrics and mattress covers to bedding manufacturers. The upholstery fabrics segment develops, sources, manufactures, and sells fabrics to residential, commercial, and hospitality furniture manufacturers. Geographically, it derives key revenue from the United States of America.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.